Derma Sciences (DSCI) to Acquire BioD in ~$77.8M Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq post best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Derma Sciences (DSCI) Enters Agreement to Sell FAD Division in $12.2M Deal
July 27, 2016 7:49 AM EDTDerma Sciences, Inc. (Nasdaq: DSCI) announces the signing of a definitive agreement to sell its First Aid Division (FAD) to Dukal Corporation for approximately $12.2 million, including inventory. Dukal is a privately-held supplier of a broad range of best-in-class disposable medical products and patient-care items for all medical markets, with headquarters in Ronkonkoma, N.Y.
Terms of the agreement call for an immediate payment at closing to Derma Sciences of $9.5 million in cash. In addition, Derma Sciences will hold a... More
